Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine.

Journal Article (Journal Article)

Protection against zoster conferred by zoster vaccine live (ZVL; Zostavax) wanes over time. We compared varicella-zoster virus cell-mediated immunity (VZV-CMI) of adults ≥70 years who received a second dose of ZVL ≥10 years after the initial dose with de novo-immunized age-matched controls. Before and during the first year after vaccination, VZV-CMI was significantly higher in reimmunized compared with de novo vaccinees. At 3 years, VZV-CMI differences between groups decreased and only memory responses remained marginally higher in reimmunized participants. In conclusion, the increase in VZV-CMI generated by reimmunization with ZVL is at least equally persistent compared with de novo immunization.

Full Text

Duke Authors

Cited Authors

  • Weinberg, A; Popmihajlov, Z; Schmader, KE; Johnson, MJ; Caldas, Y; Salazar, AT; Canniff, J; McCarson, BJ; Martin, J; Pang, L; Levin, MJ

Published Date

  • January 7, 2019

Published In

Volume / Issue

  • 219 / 2

Start / End Page

  • 335 - 338

PubMed ID

  • 30165651

Electronic International Standard Serial Number (EISSN)

  • 1537-6613

Digital Object Identifier (DOI)

  • 10.1093/infdis/jiy514


  • eng

Conference Location

  • United States